Ex­clu­sive: Roche tees up $3B+ for Shape's RNA edit­ing plat­form, with the bold promise of 'one-time' cures for Alzheimer's, Parkin­son's

Alzheimer’s and Parkin­son’s are two of the tough­est nuts to crack in bio­phar­ma. Many have tried to de­vel­op ef­fec­tive ther­a­pies and many have failed, lead­ing Big Phar­ma to re­cede from neu­ro­science in the late 2000s and ear­ly 2010s. Even for Bio­gen’s con­tro­ver­sial Aduhelm ap­proval, the first new Alzheimer’s drug in near­ly 20 years, sig­nif­i­cant ques­tions re­main re­gard­ing its ef­fec­tive­ness.

None of that is scar­ing Roche, how­ev­er, as the Swiss drug­mak­er is can­non­balling straight in­to the deep end with a new col­lab­o­ra­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER